The LATAM women hypoactive sexual desire disorder treatment market accounted for $967 million in 2019, and is expected to reach $1,275 million by 2027, registering a CAGR of 6.1% from 2020 to 2027.
Background: Buspirone is a partial 5-HT 1A receptor agonist. Animal studies have shown that modulation of serotoninergic transmission at the 5-HT 1A receptor can induce analgesia in acute pain models.